Results 61 to 70 of about 382 (79)

Globotriaosylceramide Gb3 Influences Wound Healing and Scar Formation by Orchestrating Fibroblast Heterogeneity. [PDF]

Adv Sci (Weinh)
Xie S, Huang R, Qian W, Ding X, Zhang W, Li Y, Lu J, Sun H, Liu Y, Yao Y, Lu B, Wu M, Xia Z, Ji S.   +13 more
europepmc   +1 more source

Comparison and identification of serum metabolomic profiles in Stage B and Stage C ejection fraction preserved heart failure. [PDF]

Front Cardiovasc Med
Zou S, Zhang LW, Wang T, Wan YH, Chai K, Wang SM, Meng C, Cai JP, Wang H, Yang JF.   +9 more
europepmc   +1 more source

STARD10 regulates human pancreatic β cell differentiation and triglyceride metabolism. [PDF]

Stem Cell Reports
Tan WX, Amirruddin NS, Lim EXH, Hu M, Muralidharan S, Benke PI, Torta F, Hoon S, Soetedjo AAP, Lau HH, Ng NHJ, Rutter GA, Teo AKK.   +12 more
europepmc   +1 more source

Lectin-Based Substrate Detection in Fabry Disease Using the Gb3-Binding Lectins StxB and LecA. [PDF]

Int J Mol Sci
Elçin-Guinot S, Lagies S, Avi-Guy Y, Neugebauer D, Huber TB, Schell C, Kammerer B, Römer W.   +7 more
europepmc   +1 more source

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors. [PDF]

Oncoimmunology
Möhn N, Narten E, Duzzi L, Thomas J, Grote-Levi L, Beutel G, Fröhlich T, Bollmann BA, Wirth T, von Wasielewski I, Gutzmer R, Heidel F, Pessler F, Zobl W, Schuchardt S, Ivanyi P, Nay S, Skripuletz T.   +17 more
europepmc   +1 more source

Glycosphingolipids and their impact on platelet activity in a murine model of fabry disease. [PDF]

Sci Rep
Kanack AJ, Prodoehl E, Ishihara-Aoki M, Aoki K, Dahms NM.   +4 more
europepmc   +1 more source

Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients. [PDF]

PLoS One
Kugadas A, Artoni P, Ruangsiriluk W, Zhao M, Boukharov N, Islam R, Volfson D, Derakhchan K.   +7 more
europepmc   +1 more source

A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. [PDF]

J Inherit Metab Dis
Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, Wallace E, Deegan P, Tøndel C, Feldt-Rasmussen U, Hughes D, Sakov A, Rocco R, Almon EB, Alon S, Chertkoff R, Warnock DG, Waldek S, Wilcox WR, Bernat JA.   +19 more
europepmc   +1 more source

Progress and Challenges in the Treatment of Fabry Disease. [PDF]

BioDrugs
Lenders M, Menke ER, Brand E.
europepmc   +1 more source

Metabolomic profiling of neat uterine luminal fluid in cows: local enrichment and nutritional modulation. [PDF]

Vet Q
Sagheer M, Hoorn QA, Maldonado MB, Schalich KM, Ashrafi N, A Mimi R, Graham SF, Selvaraj V, Hansen PJ.   +8 more
europepmc   +1 more source